EGFR and non-small cell lung carcinoma: Currently, two treatment options are available for patients with epidermal growth factor receptor (EGFR) T790M-positive non-small-cell lung cancer (NSCLC) who experienced disease progression following first- and second-generation EGFR-tyrosine kinase inhibitor (TKI) therapies in South Korea.